Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1JCLB | ISIN: FR0011049824 | Ticker-Symbol: 4ZG
Frankfurt
06.06.25 | 08:14
2,150 Euro
-2,05 % -0,045
Branche
Software
Aktienmarkt
Sonstige
1-Jahres-Chart
MEDIAN TECHNOLOGIES Chart 1 Jahr
5-Tage-Chart
MEDIAN TECHNOLOGIES 5-Tage-Chart
RealtimeGeldBriefZeit
2,1452,17016:42

Aktuelle News zur MEDIAN TECHNOLOGIES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
28.05.Median Technologies announces the availability of the preparatory documents for the Shareholders' Ordinary and Extraordinary General Meeting on June 17, 2025279Regulatory News: The shareholders of Median Technologies (FR0011049824, ALMDT, PEA/PME scheme eligible, "Median" or "The Company") are invited to participate in the Shareholders' Ordinary and Extraordinary...
► Artikel lesen
MEDIAN TECHNOLOGIES Aktie jetzt für 0€ handeln
27.05.Median Technologies to Showcase iCRO's Central and AI-Powered Imaging Services for Oncology Clinical Trials at ASCO 2025226Median is a leading provider of imaging services to the world's top oncology pharma companies ASCO abstracts position Median as highly differentiated provider of AI-imaging services for...
► Artikel lesen
16.05.Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of April 30, 2025262Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations. Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares ...
► Artikel lesen
14.05.Median Technologies submits U.S. application for 510(k) clearance of eyonis LCS232Submission based on positive data from two pivotal studies, which both met their primary endpoints U.S. clearance expected in Q3 2025 based on average observed review timelines for radiological...
► Artikel lesen
12.05.Median Technologies to Present Scientific Posters on eyonis LCS in Two Major Health Conferences in North America in May 2025223Projected economic benefits of using AI-powered detection/diagnostic Software as a Medical Device, like eyonis® LCS, will be presented at ISPOR 2025, the annual conference of the leading professional...
► Artikel lesen
06.05.Median Technologies to Participate in Several Investor Conferences in May and June 2025254Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, "Median" or the "Company"), manufacturer of eyonis, a suite of artificial intelligence (AI) powered Software...
► Artikel lesen
29.04.Median Technologies Reports Full-year 2024 Financial Results343Returns to FY revenue growth in 2024 (+3.3%), with acceleration in H2 (+10.2%) Slight decrease in operating loss, from €23.1 million in 2023 to €22.5 million in 2024 Operational...
► Artikel lesen
24.04.Median Technologies Reports 2025 Q1 Key Financial Indicators and Provides an Update on Q1 Key Operational Achievements299€6.0 million in Q1 2025 revenues, up 11% over Q1 2024 €74.8 million all-time high order backlog as of March 31, 2025 eyonis LCS pivotal RELIVE study met all key endpoints U.S....
► Artikel lesen
07.04.Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of March 31, 2025175Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations. Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares ...
► Artikel lesen
31.03.eyonis LCS, Median Technologies' AI-Powered Software as a Medical Device for Lung Cancer Screening, Confirmed Efficacy and Safety in RELIVE Pivotal Study290All secondary endpoints required to support eyonis LCS' intended use and desired marketing claims achieved in RELIVE eyonis LCS previously met primary endpoint, achieving statistically...
► Artikel lesen
07.03.Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of February 28, 2025352Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations. Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares ...
► Artikel lesen
03.03.Median Technologies Announces the Availability of the Preparatory Documents for the Shareholders' Extraordinary General Meeting on March 20, 2025257Regulatory News: The shareholders of Median Technologies (FR0011049824, ALMDT, PEA/PME scheme eligible, "Median" or "The Company") are invited to participate in the Shareholders' Extraordinary...
► Artikel lesen
26.02.Median Technologies to Present at TD Cowen's 45th Annual Health Care Conference254Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA/SME eligible, "Median" or "The Company"), a leading developer of eyonis, a suite of artificial intelligence (AI) powered Software...
► Artikel lesen
24.02.Median Technologies to Showcase Its Artificial Intelligence Software as a Medical Device for Lung Cancer Screening, eyonis LCS, at the European Congress of Radiology259Industry presentation at the AI Theatre: "eyonis LCS: Pioneering AI/ML Software as a Medical Device Redefining the Future of Lung Cancer Screening Median eyonis teams will be at booth AI-18...
► Artikel lesen
11.02.Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of January 31st, 2025265Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations. Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares...
► Artikel lesen
05.02.Median Technologies Gives Update on Drawdowns of the Iris Equity Line307Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA/SME scheme eligible), a leading developer of eyonis, a suite of artificial intelligence (AI) powered Software as a Medical Device...
► Artikel lesen
03.02.Median Technologies: eyonis Lung Cancer Screening (LCS) Meets Primary Endpoint in RELIVE Clinical Trial, the Final Pivotal Study Required for Regulatory Submissions293Primary endpoint met with statistical significance (p=0.027) in pivotal RELIVE trial of eyonis LCS, Median's AI/ML-based Software as a Medical Device for lung cancer screening eyonis LCS...
► Artikel lesen
31.01.Median Technologies Reports 2024 Key Financial Indicators and 2025 Outlook370H2 2024 revenue €12.0 million up 10.2% compared to H2 2023 FY 2024 revenue €22.9 million up 3.3% compared to 2023 Growing order backlog at €71.0 million, as of December 31, 2024...
► Artikel lesen
24.01.Median Technologies securing up to €47.5 million to support AI lung cancer diagnostic eyonis regulatory filings and commercialization in U.S. and EU422Repayment of 2020 EIB loan to be rescheduled to October 2025 from April New €37.5 million 2025 EIB loan under appraisal, final authorization stage New up to €10 million equity line...
► Artikel lesen
14.01.Median Technologies: Financial Communications Schedule for the First Half of 2025481Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible), announces the publication date for its 2024 results: Publication Date ...
► Artikel lesen
Weiter >>
41 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1